| Intra-aortic balloon counterpulsation in patients with acute myocardial infarction without cardiogenic shock. A meta-analysis of randomized trials. | |
| | |
MedLine Citation:
|
PMID: 22795283 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
BACKGROUND: Conflicting data on intra-aortic balloon counterpulsation (IABC) as adjunctive therapy in high-risk acute myocardial infarction (AMI) without cardiogenic shock (CS) have been published. We performed a meta-analysis of randomized trials evaluating the benefits of IABC in patients with AMI without CS. METHODS: We searched Medline, EMBASE, the Cochrane Central Register of Controlled Trials, and relevant Web sites for randomized trials comparing IABC versus no IABC in patients with AMI without CS. No language, publication date, or publication status restrictions were applied. Primary end point was all-cause death. Secondary end points were congestive heart failure (CHF), reinfarction, recurrent myocardial ischemia, cerebrovascular accidents (CVA), and bleeding (moderate to severe) according to per protocol definitions. RESULTS: Six trials were included (1,054 patients, 49.1% IABC vs 50.9% no IABC). At follow-up, counterpulsation does not reduce all-cause death (4.4% vs 4.1%, odds ratio [OR] [95% CI] 1.11 [0.49-2.54], P = .80), CHF (17.1% vs 18%, OR 0.92 [0.43-1.96], P = .83), or reinfarction (5.3% vs 7.7%, OR 0.68 [0.23-1.76], P = .42). Intra-aortic balloon counterpulsation versus no IABC significantly reduces recurrent myocardial ischemia (3.6% vs 20.3%, OR 0.15 [0.08-0.28], P < .00001), but it increases the risk of CVA (2% vs 0.3%, OR 4.39 [1.11-17.36], P = .03) and bleeding (21.4% vs 16.1%, respectively, OR 1.46 [1.05-2.04], P = .02). CONCLUSIONS: Counterpulsation does not reduce death, CHF, or reinfarction in patients with AMI without CS. The significant reduction of recurrent myocardial ischemia associated with IABC use is offset by a higher risk of CVAs and bleeding. |
| | |
Authors:
|
Salvatore Cassese; Antoinette de Waha; Gjin Ndrepepa; Sabine Ranftl; Lamin King; Albert Schömig; Adnan Kastrati |
Related Documents
:
|
21716093 - Tricuspid valve repair in patients supported with left ventricular assist devices. 22903683 - Lymphocyte subset characterization in patients with early clinical presentation of coro... 19345303 - Analysis of the origin of cardiac wall motion that constitutes myocardial velocity-time... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: American heart journal Volume: 164 ISSN: 1097-6744 ISO Abbreviation: Am. Heart J. Publication Date: 2012 Jul |
Date Detail:
|
Created Date: 2012-07-16 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0370465 Medline TA: Am Heart J Country: United States |
Other Details:
|
Languages: eng Pagination: 58-65.e1 Citation Subset: AIM; IM |
Copyright Information:
|
Copyright © 2012 Mosby, Inc. All rights reserved. |
Affiliation:
|
Deutsches Herzzentrum, Technische Universität, Munich, Germany. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Characteristics and in-hospital outcomes of patients presenting with non-ST-segment elevation myocar...
Next Document: Prevalence of Takotsubo cardiomyopathy in the United States.